Editorial: Immune-related adverse Events (irAEs) of biopharmaceuticals

Editorial: Immune-related adverse Events (irAEs) of biopharmaceuticals

Bibliographic Details
Main Authors:	Alexander Batista-Duharte, Salvador F. Aliño
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-05-01
Series:	Frontiers in Allergy
Subjects:	immune-related adverse events (irAEs) proteins nucleic acids polysaccharides cell-based therapy delivery systems
Online Access:	https://www.frontiersin.org/articles/10.3389/falgy.2023.1214914/full

Similar Items

Review of Immune-Related Adverse Events (irAEs) in Non-Small-Cell Lung Cancer (NSCLC)—Their Incidence, Management, Multiorgan irAEs, and Rechallenge
by: Raju Vaddepally, et al.
Published: (2022-03-01)

Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
by: Vivek Kumar, et al.
Published: (2017-02-01)

Upper Gastrointestinal Tract IrAEs: A Case Report About Sintilimab-Induced Acute Erosive Hemorrhagic Gastritis
by: Qi Ai, et al.
Published: (2022-06-01)

Tissue-resident memory T cells in immune-related adverse events: friend or foe?
by: Robin Reschke, et al.
Published: (2023-12-01)

External validation of biomarkers for immune-related adverse events after immune checkpoint inhibition
by: Gunther Glehr, et al.
Published: (2022-09-01)

Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors
by: Ben Ponvilawan, et al.
Published: (2024-03-01)

Meta‐analysis of immune‐related adverse events of immune checkpoint inhibitor therapy in cancer patients
by: Peng Song, et al.
Published: (2020-09-01)

Anti-GAD65 Antibody-Associated Autoimmune Encephalitis With Predominant Cerebellar Involvement Following Toripalimab Treatment: A Case Report of a Novel irAE of Toripalimab
by: Huanyu Zhou, et al.
Published: (2022-03-01)

Investigating the Impact of Immune-Related Adverse Events, Glucocorticoid Use and Immunotherapy Interruption on Long-Term Survival Outcomes
by: Charline Lafayolle de la Bruyère, et al.
Published: (2021-05-01)

Management of immune checkpoint inhibitor‐related dermatologic adverse events
by: Xiaoyan Si, et al.
Published: (2020-02-01)

Anti-PD-1 immune-related adverse events are associated with high therapeutic antibody fixation on T cells
by: Marianne Gazzano, et al.
Published: (2022-12-01)

Predictive Biomarkers of Severe Immune-Related Adverse Events With Immune Checkpoint Inhibitors: Prevention, Underlying Causes, Intensity, and Consequences
by: Ana Cardeña-Gutiérrez, et al.
Published: (2022-06-01)

Editorial: Immune-related adverse events for patients with lung cancer-volume II
by: Yusha Wang, et al.
Published: (2023-11-01)

Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study
by: Xiaohong Xie, et al.
Published: (2022-07-01)

Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer
by: Patricia Iranzo, et al.
Published: (2022-05-01)

Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events
by: Heinz Läubli, et al.
Published: (2018-05-01)

Organ-Specific Immune-Related Adverse Events for PD-1 Antibodies in Lung Cancer Treatment
by: Xiaohu Zheng, et al.
Published: (2021-05-01)

Insights Into the Host Contribution of Endocrine Associated Immune-Related Adverse Events to Immune Checkpoint Inhibition Therapy
by: Adrian Chye, et al.
Published: (2022-07-01)

Relationship between immune‐related adverse events and treatment effectiveness in extensive disease small cell lung cancer
by: Keiki Yokoo, et al.
Published: (2023-08-01)

HLA inherence as a potential parameter in checkpoint inhibitor-associated autoimmune adverse event assessment
by: Sophia Gandarillas, et al.
Published: (2024-01-01)

Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
by: Agnese Paderi, et al.
Published: (2021-02-01)

A case of urticarial vasculitis associated with atezolizumab
by: Jade N. Young, BS, et al.
Published: (2024-01-01)

Impact of patient-reported outcomes on symptom monitoring during treatment with checkpoint inhibitors: health-related quality of life among melanoma patients in a randomized controlled trial
by: Lærke K. Tolstrup, et al.
Published: (2022-01-01)

The role of tissue-resident memory T cells as mediators for response and toxicity in immunotherapy-treated melanoma—two sides of the same coin?
by: Robin Reschke, et al.
Published: (2024-03-01)

Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC
by: Biagio Ricciuti, MD, et al.
Published: (2020-11-01)

Hypothyroidism as an immune-related adverse event caused by atezolizumab in a patient with muscle spasms: a case report
by: Masanori Kawataki, et al.
Published: (2022-01-01)

Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases
by: Betul Ibis, et al.
Published: (2023-06-01)

Treatment-related hemophagocytic lymphohistiocytosis due to atezolizumab: a case report and review of the literature
by: Jaime Rubio-Perez, et al.
Published: (2022-10-01)

Challenges and Limitations of Endocrine Toxicity Evaluation in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy—Retrospective Study from a Tertiary-Level Hospital in Romania
by: Simona Coniac, et al.
Published: (2023-05-01)

Hypothesis for the development of immune-related adverse events in immune checkpoint inhibitors therapy
by: Rashida Orlova, et al.
Published: (2022-01-01)

Cutaneous Adverse Reactions of Immunotherapy in Patients with Advanced Melanoma
by: Vasiliki Nikolaou, et al.
Published: (2023-03-01)

Immune Checkpoint Inhibitors for the Therapy of Thymoma
by: Alicia Quilez, MD, et al.
Published: (2020-03-01)

Elucidation of the Application of Blood Test Biomarkers to Predict Immune-Related Adverse Events in Atezolizumab-Treated NSCLC Patients Using Machine Learning Methods
by: Jian-Guo Zhou, et al.
Published: (2022-06-01)

Immune-related adverse events correlate with the efficacy of PD-1 inhibitors combination therapy in advanced cholangiocarcinoma patients: A retrospective cohort study
by: Yanfang Zhang, et al.
Published: (2023-03-01)

The association between aspirin use and immune-related adverse events in specific cancer patients receiving ICIs therapy: analysis of the FAERS database
by: Huaju Yang, et al.
Published: (2023-11-01)

Patterns of immunotherapy-induced pneumonitis in patients with non-small-cell lung cancer: a case series
by: Sarah Picard, et al.
Published: (2021-07-01)

Immune-Related Adverse Events Due to Cancer Immunotherapy: Immune Mechanisms and Clinical Manifestations
by: Silvia Casagrande, et al.
Published: (2024-04-01)

Insights into Potential Pathogenesis and Treatment Options for Immune-Checkpoint Inhibitor-Related Pneumonitis
by: Hiroyuki Ando, et al.
Published: (2021-10-01)

Pharmacological Treatments Available for Immune-Checkpoint-Inhibitor-Induced Colitis
by: Sae Ohwada, et al.
Published: (2022-06-01)

Rapidly progressing dyspnea and retiform purpura
by: Bianca Y. Kang, MD, et al.
Published: (2022-12-01)